Rehmann Capital Advisory Group’s CRISPR Therapeutics CRSP Stock Holding History

Rehmann Capital Advisory Group’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-361	Closed	-$622K	–	572
2021 Q3	$622K	Sell	361 -7,301	-95%	-$917K	0.06%	277
2021 Q2	$1.32M	Buy	+7,662	New	+$932K	0.13%	135
2020 Q2	–	Sell	-12,336	Closed	-$523K	–	421
2020 Q1	$523K	Buy	+12,336	New	+$637K	0.09%	195
2019 Q3	$1.27K	Hold	31	–	–	﹤0.01%	1513
2019 Q2	$1.46K	Hold	31	–	–	﹤0.01%	1849
2019 Q1	$1.11K	Hold	31	–	–	﹤0.01%	1911
2018 Q4	$885	Hold	31	–	–	﹤0.01%	1680
2018 Q3	$1.37K	Hold	31	–	–	﹤0.01%	1907
2018 Q2	$1.82K	Buy	+31	New	+$1.77K	﹤0.01%	1830

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Rehmann Capital Advisory Group's CRSP Position: Q4 2021 in Review

Rehmann Capital Advisory Group sold out of CRISPR Therapeutics (CRSP) in Q4 2021, closing a stake of 361 shares — an estimated $622K sold.

Rehmann Capital Advisory Group first reported a position in CRSP in Q2 2018 and held it in 9 quarters. The position peaked at $1.32M in Q2 2021. 446 funds tracked by Wall St. Rank hold CRSP as of Q4 2021.

Rehmann Capital Advisory Group reported no remaining CRISPR Therapeutics position as of Q4 2021 after selling out during the quarter.
Rehmann Capital Advisory Group sold 361 CRISPR Therapeutics shares in Q4 2021, an estimated $622K.
Rehmann Capital Advisory Group first reported a position in CRISPR Therapeutics in Q2 2018 and held it in 9 quarters.
Rehmann Capital Advisory Group's CRISPR Therapeutics position peaked at $1.32M in Q2 2021.
446 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q4 2021.

Based on Rehmann Capital Advisory Group's 13F filing for Q4 2021, filed 2 Mar 2022.